Neurobo Pharmaceuticals Stock Price To Earnings To Growth
NRBODelisted Stock | USD 2.26 0.06 2.59% |
Neurobo Pharmaceuticals fundamentals help investors to digest information that contributes to Neurobo Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Neurobo Stock. The fundamental analysis module provides a way to measure Neurobo Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Neurobo Pharmaceuticals stock.
Neurobo |
Neurobo Pharmaceuticals Company Price To Earnings To Growth Analysis
Neurobo Pharmaceuticals' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
Competition |
Based on the latest financial disclosure, Neurobo Pharmaceuticals has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Price Transformation Now
Price TransformationUse Price Transformation models to analyze the depth of different equity instruments across global markets |
All Next | Launch Module |
Neurobo Fundamentals
Return On Equity | -1.61 | |||
Return On Asset | -0.74 | |||
Current Valuation | (1.18 M) | |||
Shares Outstanding | 8.62 M | |||
Shares Owned By Insiders | 65.23 % | |||
Shares Owned By Institutions | 12.71 % | |||
Number Of Shares Shorted | 34.27 K | |||
Price To Earning | (1.44) X | |||
Price To Book | 1.57 X | |||
Revenue | 7 K | |||
EBITDA | (15.88 M) | |||
Net Income | (12.47 M) | |||
Cash And Equivalents | 8.85 M | |||
Cash Per Share | 9.96 X | |||
Total Debt | 203 K | |||
Debt To Equity | 0.01 % | |||
Current Ratio | 8.07 X | |||
Book Value Per Share | 1.50 X | |||
Cash Flow From Operations | (10.8 M) | |||
Short Ratio | 0.87 X | |||
Earnings Per Share | (4.29) X | |||
Target Price | 26.67 | |||
Beta | -0.28 | |||
Market Capitalization | 20.33 M | |||
Total Asset | 22.78 M | |||
Retained Earnings | (108.27 M) | |||
Working Capital | 16.55 M | |||
Current Asset | 21.62 M | |||
Current Liabilities | 11.75 M | |||
Net Asset | 22.78 M |
About Neurobo Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Neurobo Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neurobo Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neurobo Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Neurobo Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Neurobo Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neurobo Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Neurobo Stock
0.81 | PPERY | Bank Mandiri Persero | PairCorr |
0.8 | PPERF | Bank Mandiri Persero | PairCorr |
0.72 | BKRKF | PT Bank Rakyat | PairCorr |
0.82 | BKRKY | Bank Rakyat | PairCorr |
Moving against Neurobo Stock
0.83 | CSCO | Cisco Systems | PairCorr |
0.8 | AXP | American Express Fiscal Year End 24th of January 2025 | PairCorr |
0.77 | BAC | Bank of America Fiscal Year End 10th of January 2025 | PairCorr |
0.77 | HD | Home Depot | PairCorr |
0.71 | DIS | Walt Disney Sell-off Trend | PairCorr |
The ability to find closely correlated positions to Neurobo Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Neurobo Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Neurobo Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Neurobo Pharmaceuticals to buy it.
The correlation of Neurobo Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Neurobo Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Neurobo Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Neurobo Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurobo Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Other Consideration for investing in Neurobo Stock
If you are still planning to invest in Neurobo Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neurobo Pharmaceuticals' history and understand the potential risks before investing.
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Transaction History View history of all your transactions and understand their impact on performance | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |